QQ客服 官方微博 反馈留言

浏览/检索结果: 共11条，第1-10条 帮助 限定条件 发表日期：2022     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 PD-L1 Aptamer-Functionalized Metal-Organic Framework Nanoparticles for Robust Photo-Immunotherapy against Cancer with Enhanced Safety 期刊论文 ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2022, 页码: 9 作者:  Zhang, Jingfang;  Li, Wenzhe;  Qi, Yafei;  Wang, Guorong;  Li, Lele 收藏  |  浏览/下载：11/0  |  提交时间：2023/02/22 DNA Nanotechnology  Immunotherapy  Metal-Organic Frameworks  PD-L1 Aptamer  Spherical Nucleic Acids (SNAs)   Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors 期刊论文 BMC Medicine, 2022, 卷号: 20, 期号: 1 作者:  Zhang,Pei;  Du,Yang;  Bai,Hua;  Wang,Zhijie;  Duan,Jianchun 收藏  |  浏览/下载：123/0  |  提交时间：2022/11/21 Tucidinostat  Tumor microenvironment  PD-L1  CCL5  Solid tumor   Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study 期刊论文 EUROPEAN JOURNAL OF CANCER, 2022, 卷号: 174 作者:  Wang, Wenxian;  Lin, Gen;  Guan, Yelan;  Zhang, Yuxin;  Xu, Chunwei 收藏  |  浏览/下载：20/0  |  提交时间：2022/12/23 Thymic carcinoma  Immunotherapy  PD-1  Efficacy  Immune-related adverse events   The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study 期刊论文 CANCERS, 2022, 卷号: 14 作者:  Xie, Mingying;  Li, Na;  Xu, Xiaoling;  Xu, Yanjun;  Li, Hui 收藏  |  浏览/下载：23/0  |  提交时间：2022/12/22 liver metastasis  non-small cell lung cancer  PD-L1  PD-1  PD-L1 inhibitor  CD8+T cell   Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2022, 卷号: 17 作者:  Wu, Y. -L.;  Zhou, Q.;  Chen, M.;  Pan, Y.;  Jian, O. 收藏  |  浏览/下载：21/0  |  提交时间：2022/12/23 CCRT  sCRT  PD-L1 inhibitor   CD3D Is an Independent Prognostic Factor and Correlates With Immune Infiltration in Gastric Cancer 期刊论文 FRONTIERS IN ONCOLOGY, 2022, 卷号: 12 作者:  Yuan, Li;  Xu, Jingli;  Shi, Yunfu;  Jin, Zhiyuan;  Bao, Zhehan 收藏  |  浏览/下载：12/0  |  提交时间：2022/12/23 gastric cancer  cd3d  tumor infiltrating lymphocytes (TILs)  prognosis  PD-L1   Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study 期刊论文 GENES CHROMOSOMES & CANCER, 2022 作者:  Wang, Wenxian;  Gu, Xiaodong;  Si, Jinfei;  Pu, Xingxiang;  Wang, Liping 收藏  |  浏览/下载：31/0  |  提交时间：2022/05/16 BRAF mutation  immune checkpoint inhibitors  non-small cell lung cancer  PD-L1  targeted therapy   Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk 期刊论文 TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 页码: 23 作者:  He, Bing-Xi;  Zhong, Yi-Fan;  Zhu, Yong-Bei;  Deng, Jia-Jun;  Fang, Meng-Jie 收藏  |  浏览/下载：31/0  |  提交时间：2022/06/10 Tumor biomarkers  immunotherapy  lung neoplasms  programmed cell death 1 receptor (PD-1 receptor)  biostatistics   Case Report: Hepatic Sarcoid-Like Reaction Associated With Checkpoint Inhibition in a NSCLC Patient and a Literature Review 期刊论文 FRONTIERS IN ONCOLOGY, 2022, 卷号: 12 作者:  Lin, Yuxin;  Zhu, Wei;  Wu, Bingchen;  Lan, Huiyin 收藏  |  浏览/下载：22/0  |  提交时间：2022/05/16 Sarcoid-like reaction  immune checkpoint inhibitor  Toripalimab  PD-1  case report   High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma 期刊论文 BMC CANCER, 2022, 卷号: 22 作者:  Chen, Xi;  Kong, Haiying;  Luo, Linxiang;  Han, Shuiyun;  Lei, Tao 收藏  |  浏览/下载：43/0  |  提交时间：2022/02/14 Hodgkin lymphoma  PD-1 inhibitor  PD-L1 inhibitor  PD-L2  Molecular phenotype  Tumor microenvironment